Edward Smith Net Worth

Edward Smith biography

Dr. Edward F. Smith III., Ph.D. serves as Senior Vice President - Regulatory Affairs and Quality Assurance of the Company. Dr. Smith previously served as Vice President, Regulatory Affairs and Drug Safety at Zogenix, Inc. from October 2008 to March 2016 and prior to that as Senior Director, Regulatory Affairs from April 2007 to October 2008. Before joining Zogenix, he served as Senior Director, Regulatory Affairs at Connetics Corp. from 2006 to 2007; Director, Regulatory Affairs at Nektar Therapeutics from 2004 to 2006; Director, Corporate Regulatory Affairs at Valeant Pharmaceuticals from 2001 to 2004; and Vice President, Regulatory Affairs and Research & Development at Radiance Medical Systems, Inc., from 1999 to 2001. He previously held research and development positions at Mallinckrodt Inc. from 1992 to 1999, at SmithKline Beecham Pharmaceuticals from 1986 to 1992, and at Ciba-Geigy from 1984 to 1985. Dr. Smith held postdoctoral fellowships at the Institute of Pharmacology at the University of Koln in Germany, and the Medical University of South Carolina. Dr. Smith received a B.S. in biology from Montana State University, a Ph.D. in physiology from Thomas Jefferson University, and an M.B.A. from Washington University. He also holds a Regulatory Affairs Certification.

How old is Edward Smith?

Edward Smith is 65, he's been the Senior Vice President - Regulatory Affairs and Quality Assurance of Conatus Pharmaceuticals since 2016. There are 2 older and 4 younger executives at Conatus Pharmaceuticals. The oldest executive at Conatus Pharmaceuticals, Inc. is Daniel Kisner, 73, who is the Independent Director.

What's Edward Smith's mailing address?

Edward's mailing address filed with the SEC is C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO, CA, 92127.

Insiders trading at Conatus Pharmaceuticals

Over the last 11 years, insiders at Conatus Pharmaceuticals have traded over $0 worth of Conatus Pharmaceuticals stock and bought 1,570,135 units worth $17,229,485 . The most active insiders traders include Shahzad Malik, Paul H Klingenstein és Preston Klassen. On average, Conatus Pharmaceuticals executives and independent directors trade stock every 83 days with the average trade being worth of $47,160. The most recent stock trade was executed by Steven J Mento on 4 May 2018, trading 60,000 units of CNAT stock currently worth $59,400.

What does Conatus Pharmaceuticals do?

Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.

Conatus Pharmaceuticals executives and stock owners

Conatus Pharmaceuticals executives and other stock owners filed with the SEC include:

• Steven Mento,
  Director
• Daniel Kisner,
  Independent Director
• Hayden Yizhuo Zhang,
  Director
• Brian Satz,
  Director
• Jonathan Jackson,
  Director
• Stephen Chang,
  Director
• Thomas Hubka,
  Director of Business Operations, Corporate Secretary
• Martin Latterich,
  Vice President - Technical Operations
• Edward Smith,
  Senior Vice President - Regulatory Affairs and Quality Assurance
• Daniel Ripley,
  Senior Vice President - Business Development, Program and Alliance Management
• Moya Daniels,
  Executive Vice President and Head of Regulatory, Quality and Clinical Operations
• Susan Knudson,
  Chief Financial Officer, Executive Vice President
• Gail Naughton,
  Founder, Chief Scientific Officer, Chief Business Officer
• Richard Pascoe,
  President, Chief Executive Officer, Director
• David Crean,
  Chairman of the Board
• William R Larue,
  Director
• Charles Cashion,
  SVP, Finance, CFO and Sec.
• Shahzad Malik,
  Director
• Alfred P. Spada,
  EVP, R&D and CSO
• David T Hagerty,
  EVP, Clinical Development
• Wart Harold Van,
  Director
• James Paul Scopa,
  Director
• Preston Klassen,
  Director
• David F Hale,
  Director
• Louis P Lacasse,
  Director
• Kathleen D. Scott,
  Director
• Keith W Marshall,
  EVP, COO & CFO
• Michelle L Vandertie,
  Vice President, Finance
• Venture Partners Llp Advent,
  10% owner
• Luke Foley Todd Gadicke Ans...,
  
• Bio Ventures Iv Qp Lpmpm Bi...,
  
• Gp Iii, L.L.C.Aberdare Vent...,
  
• Paul H Klingenstein,
  Director
• Marc Olivier Perret,
  Director
• Gilde Healthcare Ii U.A. Co...,
  10% owner
• Gary C. Burgess,
  Sr. VP, Clin. Res. & CMO